Use of GLP-1 Analogues in Patients with Schizophrenia and Other Neuropsychiatric Disorders: A Literature Review
DOI:
https://doi.org/10.12775/QS.2026.54.70410Keywords
Schizophrenia, GLP-1 analogues, Metabolic syndrom, antipsychotic drugs, mental disorder, cognitive disordersAbstract
Background: Schizophrenia is a chronic mental disorder associated with an increased risk of metabolic disturbances such as obesity, insulin resistance, and type 2 diabetes, as well as cognitive impairment. This is due to both the pathophysiology of the disease and the use of second-generation antipsychotics.
Aim of the study: To review the literature on the use of GLP-1 analogs in the treatment of metabolic and cognitive disorders in patients with schizophrenia and other neuropsychiatric diseases.
Methodology: The analysis was based on publications from PubMed and Google Scholar, using keywords related to schizophrenia, GLP-1 analogs, and metabolic disorders. Studies from 1999 to 2026 were analyzed.
Results: GLP1 analogs show beneficial effects on weight reduction and improvement of glucose and lipid parameters in patients with schizophrenia. There are also indications that they may impact cognitive functions and could be used in other neuropsychiatric disorders. They have a good safety profile and do not exacerbate psychotic symptoms.
Conclusion: GLP1 analogs are a promising therapeutic strategy in schizophrenia and may have broader applications in neuropsychiatric diseases; however, further clinical studies are required.
References
Kantrowitz JT. Managing Negative Symptoms of Schizophrenia: How Far Have We Come?. CNS Drugs. 2017;31(5):373-388. https://doi.org/10.1007/s40263-017-0428-x
Crawford P, Go KV. Schizophrenia. Am Fam Physician. 2022;106(4):388-396. https://www.aafp.org/pubs/afp/issues/2022/1000/schizophrenia.html
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. https://doi.org/10.1016/S2215-0366(18)30050-6
Bobes J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280-286. https://doi.org/10.4088/jcp.08m04250yel
Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int J Mol Sci. 2022;23(18):10624. Published 2022 Sep 13. https://doi.org/10.3390/ijms231810624
Govil P, Kantrowitz JT. Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape. CNS Drugs. 2025;39(3):243-262. https://doi.org/10.1007/s40263-024-01151-7
Kantrowitz JT, Correll CU, Jain R, Cutler AJ. New Developments in the Treatment of Schizophrenia: An Expert Roundtable. Int J Neuropsychopharmacol. 2023 May 31;26(5):322-330. https://doi.org/10.1093/ijnp/pyad011
Nebhinani N, Tripathi S, Suthar N, Pareek V, Purohit P, Sharma P. Correlates of Metabolic Syndrome in Patients with Schizophrenia: An Exploratory Study. Indian J Clin Biochem. 2022;37(2):232-237. https://doi.org/10.1007/s12291-020-00912-7
Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013 Oct;12(3):240-50. https://doi.org/10.1002/wps.20069
DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009 Feb;8(1):15-22. https://doi.org/10.1002/j.2051-5545.2009.tb00199.x
Sabé M, Pallis K, Solmi M, Crippa A, Sentissi O, Kaiser S. Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: A Dose-Response Meta-Analysis. J Clin Psychiatry. 2023;84(2):22r14490. Published 2023 Feb 8. https://doi.org/10.4088/jcp.22r14490
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. https://doi.org/10.1176/ajp.156.11.1686
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. https://doi.org/10.1016/s0140-6736(13)60733-3
Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. https://doi.org/10.1016/j.schres.2010.07.012
Claassen JN, Park JS. Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 - A pharmacoepidemiology study. Res Social Adm Pharm. 2021;17(6):1159-1165. https://doi.org/10.1016/j.sapharm.2020.09.001
De R, Smith ECC, Navagnanavel J, et al. The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta-analysis. Acta Psychiatr Scand. 2025;151(2):109-126. https://doi.org/10.1111/acps.13758
Siskind D, Baker A, Arnautovska U et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. The Lancet Psychiatry, 12, 493-503 https://doi.org/10.1016/S2215-0366(25)00129-4
Çakici N, Sutterland AL, Penninx BWJH, Dalm VA, de Haan L, van Beveren NJM. Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain Behav Immun. 2020;88:547-558. https://doi.org/10.1016/j.bbi.2020.04.039
Liang J, Cai Y, Xue X, et al. Does Schizophrenia Itself Cause Obesity?. Front Psychiatry. 2022;13:934384. Published 2022 Jun 23. https://doi.org/10.3389/fpsyt.2022.934384
Wu Q, Long Y, Peng X, et al. Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia. Transl Psychiatry. 2024;14(1):79. Published 2024 Feb 6. https://doi.org/10.1038/s41398-024-02800-7
Zhuo C, Zhang Q, Wang L, et al. Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia. CNS Drugs. 2024;38(1):33-44. https://doi.org/10.1007/s40263-023-01057-w
Neff LM, Kushner RF. Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes Metab Syndr Obes. 2010;3:263-273. Published 2010 Jul 20. https://doi.org/10.2147/dmsott.s6816
Diana Isaacs, Lalita Prasad-Reddy, Sneha Baxi Srivastava, Role of glucagon-like peptide 1 receptor agonists in management of obesity, American Journal of Health-System Pharmacy, Volume 73, Issue 19, 1 October 2016, Pages 1493–1507, https://doi.org/10.2146/ajhp150990
Daniel J. Drucker; Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care 21 October 2024; 47 (11): 1873–1888. https://doi.org/10.2337/dci24-0003
Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. https://doi.org/10.1001/jama.2021.1831
Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. https://doi.org/10.1136/jim-2021-001952
McIntyre, R. S. (2026). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality. Expert Opinion on Pharmacotherapy, 27(1), 1–3. https://doi.org/10.1080/14656566.2026.2621191
Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. Published online March 4, 2026. https://doi.org/10.2337/dc25-2041
Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial. JAMA Psychiatry. 2025;82(11):1065–1074. doi:10.1001/jamapsychiatry.2025.2332
Kirsten Lykkegaard, Philip J. Larsen, Niels Vrang, Camilla Bock, Troels Bock, Lotte Bjerre Knudsen. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance, schizophrenia research, volume 103, issues 1–3, 2008, pages 94-103, https://doi.org/10.1016/j.schres.2008.05.011.
Kyle D. Medak, Hesham Shamshoum, Willem T. Peppler, and David C. Wright American Journal of Physiology-Endocrinology and Metabolism 2020 319:6, E1101-E1111 https://doi.org/10.1152/ajpendo.00309.2020
Suvisaari, J., Keinänen, J., Eskelinen, S. et al. Diabetes and Schizophrenia. Curr Diab Rep 16, 16 (2016). https://doi.org/10.1007/s11892-015-0704-4
van Beveren, NJM., Schwarz, E., Noll, R. et al. Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl Psychiatry 4, e430 (2014). https://doi.org/10.1038/tp.2014.52
Benjamin I. Perry, Hannah J. Jones, Tom G. Richardson, Stan Zammit, Nicholas J. Wareham, Glyn Lewis, Peter B. Jones, Golam M. Khandaker,Common mechanisms for type 2 diabetes and psychosis: Findings from a prospective birth cohort, Schizophrenia Research, Volume 223, 2020, Pages 227-235, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2020.08.006.
Lonneke J. M. van Nimwegen, Jitschak G. Storosum, Regje M. E. Blumer, Gideon Allick, Henk W. Venema, Lieuwe de Haan, Hiske Becker, Therese van Amelsvoort, Mariette T. Ackermans, Eric Fliers, Mireille J. M. Serlie, Hans P. Sauerwein, Hepatic Insulin Resistance in Antipsychotic Naive Schizophrenic Patients: Stable Isotope Studies of Glucose Metabolism, The Journal of Clinical Endocrinology & Metabolism, Volume 93, Issue 2, 1 February 2008, Pages 572–577, https://doi.org/10.1210/jc.2007-1167
Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychological Medicine. 2017;47(6):1030-1040. https://doi.org/10.1017/S0033291716003366
Jean Pierre Lindenmayer, Anzalee Khan, Saurabh Kaushik, Amod Thanju, Rajalakshmi Praveen, Lisa Hoffman, Lata Cherath, Gladys Valdez, Deborah Wance, Relationship between metabolic syndrome and cognition in patients with schizophrenia, Schizophrenia Research, Volume 142, Issues 1–3, 2012, Pages 171-176, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2012.09.019.
Youssef Kouidrat, Ali Amad, GLP-1 agonists for metabolic disorders in schizophrenia, Schizophrenia Research, Volume 204, 2019, Pages 448-449, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2018.09.019.
Pelle MC, Zaffina I, Giofrè F, Pujia R, Arturi F. Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus. International Journal of Molecular Sciences. 2023; 24(14):11301. https://doi.org/10.3390/ijms241411301
Marine Monney, François R Jornayvaz, Karim Gariani, GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes, Diabetes & Metabolism, Volume 49, Issue 5, 2023, 101470, ISSN 1262-3636, https://doi.org/10.1016/j.diabet.2023.101470
Flintoff J, Kesby JP, Siskind D, Burne TH. Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential. Expert Opin Investig Drugs. 2021 Aug;30(8):877-891. https://doi.org/10.1080/13543784.2021.1951702
Jiaping Zheng, Yunzhen Xie, Lingjia Ren, Liqin Qi, Li Wu, Xiaodong Pan, Jianxing Zhou, Zhou Chen, Libin Liu, GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease, Molecular Metabolism, Volume 47, 2021, 101180, ISSN 2212-8778, https://doi.org/10.1016/j.molmet.2021.101180
Du H, Meng X, Yao Y and Xu J (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Front. Endocrinol. 13:1033479. https://doi.org/10.3389/fendo.2022.1033479
Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res. 2022 Dec;186:106550. https://doi.org/10.1016/j.phrs.2022.106550
McIntyre RS, Rasgon N, Goldberg J, et al. The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro-GDP): potential mechanistically informed therapeutics in the treatment and prevention of mental disorders. CNS Spectrums. 2025;30(1):e23. https://doi.org/10.1017/S1092852925000124
O’Mara, A., Mody, B.P., Mammi, M. et al. The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or Alzheimer’s disease: a meta-analysis of randomized controlled trials. Neurol Sci 47, 149 (2026). https://doi.org/10.1007/s10072-025-08602-z
Bade, S., Hurdle, M. F. B., Bade, S., Encalada, S., Kanahan-Osman, S., & Gupta, S. (2025). GLP-1 agonists: a game changer in pain treatment and addiction. Pain Management, 15(10), 753–765. https://doi.org/10.1080/17581869.2025.2536998
Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Apr 1;82(4):395-405. https://doi.org/10.1001/jamapsychiatry.2024.4789
Thomsen, M., Holst, J.J., Molander, A. et al. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology 236, 603–611 (2019). https://doi.org/10.1007/s00213-018-5089-z
Herman, R., Hayes, M., Audrain-McGovern, J. et al. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology 240, 1373–1386 (2023). https://doi.org/10.1007/s00213-023-06376-w
Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Enghusen Poulsen H, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022 Oct 10;7(19):e159863. https://doi.org/10.1172/jci.insight.159863
Li S, Sabbah SG, Kwan ATH, McIntyre RS. Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations. Eur Neuropsychopharmacol. 2025 Oct;99:56-67. https://doi.org/10.1016/j.euroneuro.2025.08.002
de Paiva, I.H.R., da Silva, R.S., Mendonça, I.P. et al. Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J Neuroimmune Pharmacol 19, 36 (2024). https://doi.org/10.1007/s11481-024-10142-w
Sass MR, Danielsen AA, Köhler-Forsberg O, Storgaard H, Knop FK, Nielsen MØ, Sjödin AM, Mors O, Correll CU, Ekstrøm C, Vinberg M, Nielsen J, Vilsbøll T, Fink-Jensen A. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open. 2023 Jan 31;13(1):e068652. https://doi.org/10.1136/bmjopen-2022-068652
Jacobsen SL, Köhler-Forsberg O, Danielsen AA, Rohde C. Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study. Psychiatry Res. 2025 Sep;351:116592. https://doi.org/10.1016/j.psychres.2025.116592
Patoulias D, Michailidis T, Dimosiari A, Fragakis N, Tse G, Rizzo M. Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biomedicines. 2023 Feb 22;11(3):669. https://doi.org/10.3390/biomedicines11030669
Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017 Feb;19(2):162-171 https://doi.org/10.1111/dom.12795
Hejdak D, Razzak AN, Sun L, Rahman M, Jha P. Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report. Cureus. 2024 Apr 29;16(4):e59319. doi:10.7759/cureus.59319
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Maja Pernal, Zofia Roguska, Paweł Poniewozik, Krzysztof Grabowski, Natalia Dziuba, Aleksandra Sim, Joanna Mioduszewska, Paweł Rot, Piotr Poniewozik, Andrzej Zuzak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 24
Number of citations: 0
